STOCK TITAN

Grifols 2021 Annual Report on Form 20-F filed with the SEC on April 29, 2022

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

BARCELONA, Spain, April 29, 2022 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS) announced that it has filed its 2021 Annual Report on Form 20-F with the United States Securities and Exchange Commission ("SEC") on April 29, 2022. Grifols' Annual Report on Form 20-F includes its audited financial statements for its fiscal year ended December 31, 2021.

The Form 20-F can be accessed electronically through the Grifols website at http://www.grifols.com/en/investors.The Form 20-F is also available on the SEC's website at http://www.sec.gov.

Grifols will deliver, within a reasonable time after request, a hard copy of the Form 20-F, including its complete audited financial statements, free of charge, to any shareholder upon request. To request a hard copy, shareholders may contact Grifols by email at investors@grifols.com to the attention of Grifols' Investor Relations & Sustainability, Re: 2021 Annual Report on Form 20-F.

About Grifols

Grifols is a global company in the health sector that has been working since 1909 to improve the health and well-being of people around the world. Its four divisions – Bioscience, Diagnostic, Hospital and Bio Supplies – develop, produce and market innovative solutions and services in more than 100 countries.

A pioneer in the blood products industry, Grifols is one of the largest plasma companies, with a growing network of donation centers around the world. With the plasma obtained, Grifols produces essential medicines to treat chronic, rare and sometimes very serious diseases. As a recognized leader in transfusion medicine, the company has a comprehensive portfolio of solutions designed to improve safety from donation to transfusion. In addition, it provides hospitals, pharmacies and health professionals with the tools, information and services that contribute to offering specialized and efficient medical care.

Grifols, with more than 23,000 employees in more than 30 countries and regions, is committed to a sustainable business model that helps define the standards of continuous innovation, quality, safety and ethical leadership in the sector.

In 2021, Grifols' total economic impact in the main countries where it operates is estimated at 7,700 million euros and 141,500 jobs generated, including direct, indirect and induced jobs.

The company's ordinary shares (Class A) are listed on the Spanish Continuous Market and form part of the Ibex-35 (MCE: GRF). Grifols non-voting shares (Class B) are listed on the Spanish Continuous Market (MCE: GRF.P) and on the North American NASDAQ through ADR (American Depositary Receipts) (NASDAQ: GRFS).

For more information: www.grifols.com

Logo - https://mma.prnewswire.com/media/847347/Grifols_Logo.jpg

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/grifols-2021-annual-report-on-form-20-f-filed-with-the-sec-on-april-29-2022-301536450.html

SOURCE Grifols

Grifois, S.A.

NASDAQ:GRFS

GRFS Rankings

GRFS Latest News

GRFS Stock Data

4.46B
546.96M
49.36%
0.88%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Barcelona

About GRFS

for more than 75 years, grifols has been improving the health and well-being of people. our patients are our priority, and our commitment to their health has enabled us to become a global healthcare leader with presence in more than 100 countries. the grifols legacy embodies a spirit of innovation and a forward thinking approach and establish us as an international benchmark in the plasma collection market, the production of plasma derived therapies and transfusion medicine. grifols has three business divisions: bioscience brings together all plasma related activities including research, development, collection, production and sales of life-saving plasma derived therapies. diagnostic provides innovative solutions to support safe and compatible transfusions, monitor therapies, and detect infectious and autoimmune diseases. research novel technologies to further improve treatment outcomes and laboratory efficiency. hospital specializes in non-biological pharmaceutical products. t